Skip to main content

International Journal of Clinical Oncology

Ausgabe 12/2023

Inhalt (15 Artikel)

Review Article

Current trends in the promising immune checkpoint inhibition and radiotherapy combination for locally advanced and metastatic urothelial carcinoma

Takeshi Sano, Ryoichi Saito, Rihito Aizawa, Tsubasa Watanabe, Kaoru Murakami, Yuki Kita, Kimihiko Masui, Takayuki Goto, Takashi Mizowaki, Takashi Kobayashi

Open Access Original Article

Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan

Tomohisa Baba, Masahiko Kusumoto, Terufumi Kato, Yasuyuki Kurihara, Shinichi Sasaki, Katsunori Oikado, Yoshinobu Saito, Masahiro Endo, Yutaka Fujiwara, Hirotsugu Kenmotsu, Masafumi Sata, Toshimi Takano, Ken Kato, Koji Hirata, Tomomi Katagiri, Hanako Saito, Kazuyoshi Kuwano

Original Article

Clinicopathological characteristics of four major histological types of high-grade parotid carcinoma

Ryo Kawata, Ichita Kinoshita, Tsuyoshi Jinnin, Masaaki Higashino, Tetsuya Terada, Yoshitaka Kurisu, Yoshinobu Hirose, Takeshi Tochizawa

Original Article

Clinical course of longer than five years after definitive radiotherapy for nasopharyngeal carcinoma

Hiroshi Doi, Aritoshi Ri, Masahiro Inada, Saori Tatsuno, Takuya Uehara, Tomohiro Matsuura, Kazuki Ishikawa, Kiyoshi Nakamatsu, Makoto Hosono, Yasumasa Nishimura

Original Article

The predictive value of advanced lung cancer inflammation index for short-term outcomes and prognosis of colorectal cancer patients who underwent radical surgery

Bin Zhang, Zi-Wei Li, Yue Tong, Chao Yuan, Xiao-Yu Liu, Zheng-Qiang Wei, Wei Zhang, Dong Peng

Original Article

Oral frailty is a risk factor for body weight loss after gastrectomy: a single-center, retrospective study

Ryugo Teranishi, Kazuyoshi Yamamoto, Yukinori Kurokawa, Toshihiro Uchihashi, Akinari Sugauchi, Chihiro Tanikawa, Kosuke Kubo, Tsuyoshi Takahashi, Takuro Saito, Kota Momose, Kotaro Yamashita, Koji Tanaka, Tomoki Makino, Kiyokazu Nakajima, Emiko Tanaka Isomura, Hidetoshi Eguchi, Yuichiro Doki

Original Article

Risk of metachronous colorectal cancer after colectomy for first colon cancer in Lynch syndrome: multicenter retrospective study in Japan

Kenichi Chikatani, Hideyuki Ishida, Yoshiko Mori, Takeshi Nakajima, Arisa Ueki, Kiwamu Akagi, Akinari Takao, Masayoshi Yamada, Fumitaka Taniguchi, Koji Komori, Kazuhito Sasaki, Tomoya Sudo, Yasuyuki Miyakura, Akiko Chino, Tatsuro Yamaguchi, Kohji Tanakaya, Naohiro Tomita, Yoichi Ajioka

Original Article

Usefulness of genotyping APC gene for individualizing management of patients with familial adenomatous polyposis

Yoshiko Mori, Hideyuki Ishida, Noriyasu Chika, Tetsuya Ito, Kunihiko Amano, Kenichi Chikatani, Yoji Takeuchi, Mitsuhiro Kono, Satoki Shichijo, Akiko Chino, Toshiya Nagasaki, Akinari Takao, Misato Takao, Sakiko Nakamori, Kazuhito Sasaki, Kiwamu Akagi, Tatsuro Yamaguchi, Kohji Tanakaya, Tomita Naohiro, Yoichi Ajioka

Original Article

Association between immune-related adverse events and survival in patients with renal cell carcinoma treated with nivolumab plus ipilimumab: immortal time bias-corrected analysis

Satoshi Washino, Suguru Shirotake, Hideki Takeshita, Masaharu Inoue, Yuji Miura, Yoji Hyodo, Makoto Kagawa, Keita Izumi, Masafumi Oyama, Satoru Kawakami, Kazutaka Saito, Yoh Matsuoka, Satsuki Taniuchi, Ayumi Shintani, Tomoaki Miyagawa

Open Access Original Article

Can contralateral lymph-node metastases be ruled out in prostate cancer patients with only unilaterally positive prostate biopsy?

Bianca Michalik, Svenja Engels, Leonie Kampmeier, Lena Dirks, R.-Peter Henke, Friedhelm Wawroschek, Alexander Winter

Open Access Original Article

Intentions for catch-up HPV vaccination in Japan: an internet survey

Satoshi Nakagawa, Asami Yagi, Yutaka Ueda, Sayaka Ikeda, Mamoru Kakuda, Kosuke Hiramatsu, Ai Miyoshi, Toshihiro Kimura, Kei Hirai, Masayuki Sekine, Tomio Nakayama, Eiji Kobayashi, Etsuko Miyagi, Takayuki Enomoto, Tadashi Kimura

Original Article

Mean platelet volume as a potential biomarker for survival outcomes in ovarian clear cell carcinoma

Nobuhisa Yoshikawa, Tetsuya Matsukawa, Satomi Hattori, Shohei Iyoshi, Kosuke Yoshida, Masato Yoshihara, Satoshi Tamauchi, Yusuke Shimizu, Yoshiki Ikeda, Akira Yokoi, Kaoru Niimi, Michiyasu Kawai, Hiroaki Kajiyama

Original Article

Prognostic factors in cutaneous apocrine carcinoma: a single-institution retrospective study of 32 patients

Seiji Tsuruta, Dai Ogata, Kenjiro Namikawa, Eiji Nakano, Kojiro Hiki, Mao Okumura, Yoshiyuki Matsui, Yuichi Nakayama, Shogo Wada, Naoya Yamazaki

Correction

Correction to: Comparison of outcomes in high‑risk prostate cancer patients treated with low‑/high‑dose‑rate brachytherapy plus external beam radiotherapy

Yu Imai, Fumihiko Urabe, Kosuke Iwatani, Minoru Nakazono, Kojiro Tashiro, Mariko Honda, Manabu Aoki, Shun Sato, Hiroyuki Takahashi, Kenta Miki, Takahiro Kimura

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.